From innovative concepts to trial readiness - Advancing clinical research in rare diseases
This session examined strategies for translating promising scientific concepts into trial-ready approaches for rare diseases, addressing the methodological and practical challenges associated with generating robust evidence in small and heterogeneous populations. Topics included innovative research methodologies, clinical trial design, patient involvement and approaches to improving research feasibility and readiness. The involvement of children and young people was recognised as an integral part of developing research approaches that reflect their experiences, needs and priorities.
Panellists:
Dariusz Damczewski
Read more
Dariusz Adamczewski, MD, is Managing Director of Children’s Tumor Foundation Europe (CTF Europe), the Brussels-based patient foundation dedicated to neurofibromatosis and schwannomatosis (NF). CTF Europe combines patient advocacy with an active role in drug development and research. He leads the development of EU-PEARL NF1, a multinational adaptive basket platform trial in neurofibromatosis type 1, and Atlas NF, a European mapping of NF clinical centres and trial-site capability, while overseeing the foundation’s research grant portfolio, pharmaceutical partnerships and health policy engagement. A physician by training, he has a career spanning clinical medicine, government and industry. He held senior positions at the Polish Ministry of Health, where he led major health system reforms, and brings industry experience from Johnson & Johnson and Pfizer. His work focuses on the infrastructure rare disease research needs to deliver for patients in Europe: regulatory science, platform and basket trial design, health economics, and sustainable funding models that bring patient organisations, academic networks, regulators and companies together around shared goals. He is a committed advocate for patient-led foundations acting as partners in research and development ecosystem.
Nunzio Denora
Read more
Nunzio Denora received his degree in Chemistry and Pharmaceutical Technology from the University of Bari in 2001 and earned a Ph.D. in Pharmaceutical Technology from the University of Palermo in 2004. He subsequently completed postdoctoral training at the University of Kansas (2005–2006) under the supervision of Prof. Valentino J. Stella. He then joined the University of Bari “Aldo Moro,” where he progressed through academic ranks and currently serves as Full
Professor of Pharmaceutical Technology and Legislation (since 2023), leading a formulation research laboratory focused on advanced drug delivery systems.
Prof. Denora coordinates the Industrial PhD program Sustainable Industrial Technologies for the Development of Therapeutics and Diagnostics (TeSSMed) and serves on the scientific advisory boards of several pharmaceutical companies. He is Secretary of the Board of the Italian Society of Pharmaceutical Technology and Legislation (SITELF), a member of the advisory boards of the Journal of Pharmaceutical Sciences, the Journal of Drug Delivery Science and Technology, and
other leading journals in pharmaceutics, and Assistant Editor of the Journal of Drug Delivery Science and Technology.
His research is centered on the design and development of pediatric and age-related pharmaceutical formulations, with particular emphasis on innovative drug delivery technologies and advanced formulation strategies.
Liisi Laaniste
Read more
Liisi holds a PhD from Imperial College London in Computational Systems Biology, focusing on the transformation of low-grade gliomas to high-grade tumours and identifying genetic vulnerabilities in glioblastoma.
At Karolinska Institute, she studied neuroscience, concentrating on the epigenetics of neural stemness. During her medical science studies at Uppsala University, where she ranked first in her class, she researched brain tumour microenvironments and vasculature. Liisi graduated cum laude from the University of Tartu, conducting research in human genetics and metabolomics.
Liisi has been awarded multiple scholarships, including the highly competitive Imperial College President’s scholarship. Liisi is driven by the intricate complexity of biology and is passionate about leveraging systems biology to bridge preclinical discoveries and patient benefit.
Michelina Armando
Read more
Professional focus on methodology, protocol design and evidence-based rehabilitation medicine dedicated to optimizing neuromotor development, functional independence and quality of life advancing innovative treatments and multidisciplinary care models.